

# Melvin L K Chua

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3184371/publications.pdf>

Version: 2024-02-01

163  
papers

7,665  
citations

126708

33  
h-index

58464

82  
g-index

174  
all docs

174  
docs citations

174  
times ranked

12544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nasopharyngeal carcinoma. <i>Lancet</i> , The, 2016, 387, 1012-1024.	6.3	1,045
2	SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. <i>JAMA Oncology</i> , 2020, 6, 1108.	3.4	862
3	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 1124-1135.	13.9	573
4	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945.	1.9	520
5	Molecular landmarks of tumor hypoxia across cancer types. <i>Nature Genetics</i> , 2019, 51, 308-318.	9.4	480
6	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017, 541, 359-364.	13.7	462
7	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	13.5	317
8	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. <i>Radiology</i> , 2019, 291, 677-686.	3.6	221
9	Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. <i>Annals of Oncology</i> , 2019, 30, 68-75.	0.6	196
10	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	0.8	178
11	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell</i> , 2018, 173, 1003-1013.e15.	13.5	176
12	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	0.9	142
13	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1345.	3.4	137
14	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , 2017, 8, 656.	5.8	100
15	Upconversion superballs for programmable photoactivation of therapeutics. <i>Nature Communications</i> , 2019, 10, 4586.	5.8	100
16	Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. <i>Nature Communications</i> , 2019, 10, 3941.	5.8	98
17	Neuropathological and transcriptomic characteristics of the aged brain. <i>ELife</i> , 2017, 6, .	2.8	97
18	Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. <i>Head and Neck</i> , 2009, 31, 346-354.	0.9	86

#	ARTICLE	IF	CITATIONS
19	Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. <i>Cancer</i> , 2020, 126, 4023-4031.	2.0	82
20	Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 891-899.	0.8	81
21	Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. <i>JAMA Oncology</i> , 2021, 7, 597.	3.4	71
22	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	3.4	64
23	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	2.3	58
24	Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. <i>Radiotherapy and Oncology</i> , 2011, 99, 362-366.	0.3	54
25	Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. <i>European Journal of Cancer</i> , 2016, 67, 119-129.	1.3	49
26	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , 2019, 25, 1615-1626.	15.2	45
27	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	3.4	44
28	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020, 146, 2305-2314.	2.3	44
29	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
30	Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20190271.	1.0	38
31	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	2.6	38
32	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	0.9	37
33	Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. <i>Annals of Oncology</i> , 2019, 30, 637-643.	0.6	37
34	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 84-91.	0.4	36
35	Dysregulation of the MiR-449b target TGFBI alters the TGF $\beta$ <sup>2</sup> pathway to induce cisplatin resistance in nasopharyngeal carcinoma. <i>Oncogenesis</i> , 2018, 7, 40.	2.1	34
36	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	5.8	34

#	ARTICLE	IF	CITATIONS
37	A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study. <i>Diagnostics</i> , 2020, 10, 959.	1.3	33
38	A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5438-5447.	3.2	32
39	Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2018, 7, 15-15.	0.4	31
40	Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e044661.	0.8	30
41	Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. <i>Cancer Communications</i> , 2020, 40, 374-379.	3.7	29
42	Recent advances in radiation therapy and photodynamic therapy. <i>Applied Physics Reviews</i> , 2021, 8, .	5.5	29
43	DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. <i>Radiation and Environmental Biophysics</i> , 2014, 53, 355-364.	0.6	28
44	Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. <i>Chinese Journal of Cancer</i> , 2016, 35, 9.	4.9	28
45	A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 672-682.	0.4	22
46	Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. <i>Radiotherapy and Oncology</i> , 2011, 99, 225-230.	0.3	21
47	De-Escalation Strategies in HPV-Associated Oropharynx Cancer—Are we Putting the Cart Before the Horse?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 705-709.	0.4	21
48	Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China. <i>JAMA Oncology</i> , 2020, 6, 1457.	3.4	21
49	Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. <i>Oral Oncology</i> , 2018, 86, 61-68.	0.8	20
50	Gemcitabine: a game changer in nasopharyngeal carcinoma. <i>Lancet, The</i> , 2016, 388, 1853-1854.	6.3	19
51	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 459-465.	0.3	18
52	Advances in nasopharyngeal carcinoma—West meets East. <i>British Journal of Radiology</i> , 2019, 92, 20199004.	1.0	17
53	Multidisciplinary team meetings—challenges of implementation science. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 205-206.	12.5	17
54	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. <i>Current Problems in Cancer</i> , 2017, 41, 265-272.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6005-6005.	0.8	16
56	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. <i>Clinical Cancer Research</i> , 2016, 22, 3124-3126.	3.2	15
57	Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 27, 367-374.	1.3	15
58	Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives. <i>Cancer Communications</i> , 2021, 41, 361-370.	3.7	15
59	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. <i>OncoTargets and Therapy</i> , 2016, 9, 1115.	1.0	14
60	Intraductal Carcinoma of the Prostate: Anonymous to Ominous. <i>European Urology</i> , 2017, 72, 496-498.	0.9	14
61	The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma. <i>Cancer Biology and Medicine</i> , 2018, 15, 1.	1.4	14
62	Matrix metalloproteinaseâ€1 facilitates <sc>MSC</sc> migration via cleavage of <sc>IGF</sc>â€2/<sc>IGFBP</sc>2 complex. <i>FEBS Open Bio</i> , 2018, 8, 15-26.	1.0	13
63	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2020, , .	2.6	13
64	A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. <i>Neurology</i> , 2020, 95, e1392-e1403.	1.5	13
65	Stereotactic body radiotherapy for early stage lung cancerâ€”historical developments and future strategies. <i>Chinese Clinical Oncology</i> , 2017, 6, S20-S20.	0.4	13
66	<sup>68</sup> Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. <i>Cancer Biology and Medicine</i> , 2019, 16, 157.	1.4	12
67	Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exomeâ€Wide Association Study in Multiple Cohorts. <i>Advanced Science</i> , 2020, 7, 1903727.	5.6	12
68	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. <i>British Journal of Cancer</i> , 2022, 126, 1082-1090.	2.9	12
69	Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 244-249.	0.3	11
70	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. <i>Oral Oncology</i> , 2021, 115, 105222.	0.8	11
71	Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. <i>Cancer Letters</i> , 2021, 511, 56-67.	3.2	11
72	Financial toxicities of cancer in lowâ€and middleâ€income countries: Perspectives from Southeast Asia. <i>Cancer</i> , 2022, 128, 3013-3015.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). <i>Radiation Oncology</i> , 2009, 4, 23.	1.2	10
74	Adaptive radiotherapy for head and neck cancers: Fact or fallacy to improve therapeutic ratio?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 287-295.	0.6	9
75	Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097005.	1.4	9
76	Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. <i>BMC Cancer</i> , 2020, 20, 1045.	1.1	9
77	Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma: innovation at the expense of uncertainty. <i>Cancer Communications</i> , 2020, 40, 119-121.	3.7	9
78	SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target. <i>Cancers</i> , 2021, 13, 4944.	1.7	9
79	Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110524.	1.4	9
80	Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. <i>Cancer Letters</i> , 2016, 374, 324-330.	3.2	8
81	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. <i>Radiotherapy and Oncology</i> , 2022, 167, 179-186.	0.3	8
82	Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. <i>Mikrochimica Acta</i> , 2022, 189, 14.	2.5	8
83	Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 75-79.	0.7	7
84	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1426-e1427.	1.9	7
85	Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. <i>Radiotherapy and Oncology</i> , 2021, 160, 140-147.	0.3	7
86	Follow-Up and Management of Patients With Head and Neck Cancer During the 2019 Novel Coronavirus (SARS-CoV-2) Disease Pandemic. <i>Advances in Radiation Oncology</i> , 2020, 5, 631-636.	0.6	6
87	Duration-dependent margins for prostate radiotherapy—a practical motion mitigation strategy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 657-663.	1.0	6
88	NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	2.0	6
89	JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps. <i>Cancer Communications</i> , 2022, 42, 56-59.	3.7	6
90	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , 2017, 2, e000123.	2.0	5

#	ARTICLE	IF	CITATIONS
91	Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2019, 39, 1-3.	3.7	5
92	Electronic tumor board presentations as the basis for the development of a head and neck cancer database. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 46-54.	0.6	5
93	Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. <i>Frontiers in Oncology</i> , 2021, 11, 746941.	1.3	5
94	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 989-998.	2.0	5
95	Managing advanced prostate cancer in the Asia Pacific region: â€œRealâ€worldâ€application of Advanced Prostate Cancer Consensus Conference 2019 statements. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 686-695.	0.7	5
96	Efficacy and Safety of Apatinib for Radiation-induced Brain Injury Among Patients With Head and Neck Cancer: An Open-Label, Single-Arm, Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 796-804.	0.4	5
97	An evaluation of concordance between head and neck advanced practice radiation therapist and radiation oncologists in toxicity assessment for nasopharyngeal carcinoma patients. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 19, 52-56.	0.6	4
98	Nasopharyngeal carcinomaâ€”past lessons and a glimpse into the future. <i>Chinese Clinical Oncology</i> , 2016, 5, 14-14.	0.4	4
99	Exploiting molecular genomics in precision radiation oncology: a marriage of biological and physical precision. <i>Chinese Clinical Oncology</i> , 2017, 6, S19-S19.	0.4	4
100	Coming of age of bevacizumab in the management of radiation-induced cerebral necrosis. <i>Annals of Translational Medicine</i> , 2019, 7, 155-155.	0.7	4
101	Adolescents and young adults with cancer: Considerations from the Southeast Asian perspective. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29593.	0.8	4
102	Efficacy, toxicity, and qualityâ€ofâ€life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A singleâ€arm phase 2 trial from Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	4
103	Circulating Tumor DNA to Personalize Treatment in Nasopharynx Cancer â€” Time to Look â€œAheadâ€?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 362-364.	0.4	3
104	The metabolic footprint during adipocyte commitment highlights ceramide modulation as an adequate approach for obesity treatment. <i>EBioMedicine</i> , 2020, 51, 102605.	2.7	3
105	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.4	3
106	Risk of COVID-19 in Patients With Cancerâ€”Reply. <i>JAMA Oncology</i> , 2020, 6, 1472.	3.4	3
107	Four Influential Clinical Trials in Human Papilloma Virus-Associated Oropharynx Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 893-899.	0.4	3
108	Reply to Colorectal cancer and COVIDâ€19: Do we need to raise awareness and vigilance?. <i>Cancer</i> , 2021, 127, 980-981.	2.0	3

#	ARTICLE	IF	CITATIONS
109	A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. <i>Acta Oncol</i> , 2021, 60, 1291-1295.	0.8	3
110	Why we should give spatially fractionated radiation therapy (GRID) a second look—especially in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , 2018, 1, 1-1.	0.5	2
111	Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC. <i>BMC Cancer</i> , 2018, 18, 1095.	1.1	2
112	Discovering biomarkers of radioresistance in a radiosensitive cancer: a clinical paradox in nasopharyngeal carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1284-1284.	0.7	2
113	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 5.e1-5.e13.	0.8	2
114	Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. <i>Clinical Oncology</i> , 2021, 33, e469-e481.	0.6	2
115	Nasopharyngeal carcinoma—some closing remarks. <i>Chinese Clinical Oncology</i> , 2016, 5, 29-29.	0.4	2
116	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—Magic Bullet or Pandora's Box?. <i>JAMA Oncology</i> , 2022, , .	3.4	2
117	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 702-709.	0.4	1
118	Immunotherapy in Head and Neck Cancer—Ready for Prime Time or More Research Needed?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 647-650.	0.4	1
119	Lymphocyte apoptosis as a predictive biomarker for radiotherapy de-intensification in EBV-associated nasopharynx cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17545-e17545.	0.8	1
120	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 46-46.	0.8	1
121	Immune dysregulation underpins radioresistance in nasopharyngeal carcinoma (NPC).. <i>Journal of Global Oncology</i> , 2019, 5, 52-52.	0.5	1
122	The promise of stereotactic body radiotherapy—next phase of integration into oncological practice. <i>Chinese Clinical Oncology</i> , 2017, 6, S8-S8.	0.4	1
123	A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6036-6036.	0.8	1
124	Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: <i>Quo Vadis</i> ?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1135-1138.	0.8	1
125	MP14-04 OUTCOMES OF RADIATION FOLLOWING EXPECTANT MANAGEMENT FOR LOW RISK, LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
126	Dosimetric uncertainties impact on cell survival curve with low energy proton. <i>Physica Medica</i> , 2020, 76, 277-284.	0.4	0



#	ARTICLE	IF	CITATIONS
127	In Reply. <i>Oncologist</i> , 2020, 25, e1252-e1253.	1.9	0
128	Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 249-249.	0.8	0
129	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e217.	5.1	0
130	PSY3-4 AI for practice. <i>Annals of Oncology</i> , 2021, 32, S241.	0.6	0
131	Something for Everyone From Low-Risk to High-Risk: 5 Recent Studies to Improve Treatment and Surveillance for All Patients With Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1-8.	0.4	0
132	Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 101-101.	0.8	0
133	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 117-117.	0.8	0
134	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016, 34, 96-96.	0.8	0
135	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2016, 34, 49-49.	0.8	0
136	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5051-5051.	0.8	0
137	Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture. , 2016, , .		0
138	Treatment of Viral-Associated HNC (OPC and NPC). , 2017, , 177-188.		0
139	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 42-42.	0.8	0
140	Genomic architecture of radioresistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 26-26.	0.8	0
141	Abstract B39: Tumor hypoxia induces DNA repair vulnerabilities through contextual loss-of-heterozygosity, 2017, , .		0
142	Abstract A28: Mutational landscape of TP53 in localized prostate cancer. , 2017, , .		0
143	Abstract 2486: Tumor hypoxia induces DNA repair vulnerabilities through contextual loss of heterozygosity. , 2017, , .		0
144	Abstract 5860: Genomic architecture of prostate cancer at recurrence following radiotherapy. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
145	Abstract 1794: Lymphocyte apoptosis as a predictive biomarker for radiotherapy de-intensification in EBV-associated nasopharynx cancer. , 2017, , .		0
146	A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 68-68.	0.8	0
147	68-Ga prostate-specific membrane antigen-PET as a diagnostic and clinical decision making tool in biochemical recurrences post-radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 377-377.	0.8	0
148	â€œCor Occidereâ€: a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. Chinese Clinical Oncology, 2018, 7, 10-10.	0.4	0
149	Retroperitoneal Knee Pain: An Unusual Case Report and Review of an Ancient Schwannoma. Cureus, 2018, 10, e2216.	0.2	0
150	A radiomics signature for treatment stratification in advanced and recurrent nasopharynx cancer.. Journal of Clinical Oncology, 2018, 36, e18060-e18060.	0.8	0
151	Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response.. Journal of Clinical Oncology, 2018, 36, 12056-12056.	0.8	0
152	Editorial Comment. Journal of Urology, 2019, 201, 291-291.	0.2	0
153	The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2019, 37, 13-13.	0.8	0
154	The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.. Journal of Clinical Oncology, 2019, 37, 81-81.	0.8	0
155	Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer.. Journal of Clinical Oncology, 2019, 37, 95-95.	0.8	0
156	Longitudinal circulating Epsteinâ€Barr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and neck cancer.. Journal of Clinical Oncology, 2019, 37, 6021-6021.	0.8	0
157	Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epsteinâ€Barr virus DNA and TNM stage: A â€œBig dataâ€ analysis of 9,160 endemic cases.. Journal of Clinical Oncology, 2019, 37, 6043-6043.	0.8	0
158	Abstract 527: High-dimensional profiling of the systemic immune response informs on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB). , 2019, , .		0
159	The hunt for the perfect biomarker in nasopharyngeal carcinomaâ€the RRAS â€œraceâ€beyond Epstein-Barr virus?. Translational Cancer Research, 2019, 8, 1659-1662.	0.4	0
160	Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, 227-227.	0.8	0
161	The Uro-Oncology Multi-disciplinary team (MDT) Clinic â€ Clinical and Patient-Reported Outcomes From Implementing a New Model of Care. Proceedings of Singapore Healthcare, 0, , 201010582110552.	0.2	0
162	In Reply to Abbasi et al.. International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263.	0.4	0

#	ARTICLE	IF	CITATIONS
163	A Bit More Here and a Little Less There: The Trials (and Tribulations) of Adjuvant and Neoadjuvant Head and Neck Studies in 2021. International Journal of Radiation Oncology Biology Physics, 2022, 113, 243-251.	0.4	0